Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) is a phase 3, randomised interventional study registered as NCT04267848 by National Cancer Institute (NCI), with a registry enrolment figure of 1210 participants, started 2020-06-16 and due to reach its primary completion in 2027-01-31. Interventions recorded: Biospecimen Collection; Carboplatin; Cisplatin; Computed Tomography; Echocardiography Test; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Observation Activity; Paclitaxel; Pembrolizumab; Pemetrexed Disodium; Questionnaire Administration. Conditions listed: Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8. Primary outcome: Disease free survival (DFS). Lung eligibility wording from the registry: "* Completely resected stage IIA, IIB IIIA or IIIB (T3-4N2) non-small cell lung cancer (NSCLC) (squamous or non-squamous) with negative margins (complete R0 resection)". Sites: Guam, United States. No results are recorded here; the registry entry is the source.